Alpha Healthcare Acquisition Corp. III
ALPAU
NASDAQ Capital Market9.75
USD
+0.31
- -
CIK
0001842939
ISIN
US02073F2039
CUSIP
02073F203
Return %
Stock
S&P500
1Y
-0.10
26.57
3Y
-2.50
76.60
5Y
-2.50
78.48
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Rajiv Sarman Shukla
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 1177 Avenue of the Americas New York City NY United States of America 10036
- IPO Date
- Jul 27, 2021
- CIK
- 0001842939
- Website
- alphaspac.com
- Similar Companies
- Business
- Alpha Healthcare Acquisition Corp. III (ALPAU) operates as a blank check company, or special purpose acquisition company (SPAC), focused on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, primarily in the healthcare sector; it conducts no significant operations prior to completing such a transaction. Incorporated in 2021 and headquartered in New York, New York, the company targets healthcare entities in the United States. In July 2023, Alpha Healthcare Acquisition Corp. III completed a reverse merger with Carmell Therapeutics Corporation, a Phase 2 stage regenerative medicine platform company developing allogeneic plasma-based biomaterials for soft tissue repair, aesthetics, and orthopedic indications, resulting in the combined entity trading as Carmell Therapeutics Corporation (Nasdaq: CTCX); the transaction yielded approximately $29.4 million in gross proceeds from the trust after redemptions. Prior to the merger closing on July 14, 2023, the company raised $150 million through its initial public offering of 15 million units in July 2021 and entered a definitive business combination agreement with Carmell in January 2023, approved by stockholders in July 2023; it also signed a non-binding letter of intent in May 2023 for a potential follow-on acquisition of a commercial-stage regenerative medicine company, conditioned on the Carmell deal. The SPAC, led by Chairman and CEO Rajiv Shukla, maintains its focus on healthcare investments without current substantive products or services beyond pursuing de-SPAC transactions.